Aldeyra Therapeutics

Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company is focused primarily on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are caused by naturally occurring toxic chemical species known as free aldehydes. The Company has developed a series of product candidates that are designed specifically to trap and allow for the degradation of free aldehydes. The Company's most advanced product candidate is an eye drop formulation of NS2, which is under development for the treatment of Sjogren-Larsson Syndrome (SLS). The Company has completed a double-masked, placebo-controlled, Phase I clinical testing of 0.25% and 0.5% NS2 administered as an eye drop for safety and tolerability in approximately 48 healthy volunteers. Data from the Phase I study demonstrated that NS2 was well tolerated in all subjects throughout the duration of the study.
Company Growth (employees)
Type
Public
HQ
Lexington, US
Founded
2004
Size (employees)
6 (est)
Aldeyra Therapeutics was founded in 2004 and is headquartered in Lexington, US

Aldeyra Therapeutics Office Locations

Aldeyra Therapeutics has an office in Lexington
Lexington, US (HQ)
131 Hartwell Ave

Aldeyra Therapeutics Data and Metrics

Aldeyra Therapeutics Financial Metrics

USD

Net income (Q1, 2017)

(5.1 m)

EBIT (Q1, 2017)

(5.1 m)

Market capitalization (21-Jul-2017)

65.5 m

Cash (31-Mar-2017)

19.3 m
Aldeyra Therapeutics's current market capitalization is $65.5 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

3.7 m7.6 m13.2 m

General and administrative expense

3.6 m4.4 m5.5 m

Operating expense total

(7.3 m)(12 m)(18.7 m)

EBIT

(18.7 m)

Interest expense

(244.2 k)(112.3 k)(105.5 k)

Interest income

311.1 k102 k

Net Income

(9.6 m)(12.1 m)(18.7 m)
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

R&D expense

3.5 m2.8 m3.4 m3.4 m

General and administrative expense

1.5 m1.5 m1.4 m1.7 m

Operating expense total

5 m4.3 m4.8 m5.1 m

EBIT

(5 m)(4.3 m)(4.8 m)(5.1 m)

Interest expense

(25 k)(27.8 k)(26.7 k)(26.8 k)

Interest income

24.7 k22 k27.8 k31.6 k

Net Income

(4.4 m)(7.7 m)(5 m)(9.3 m)(14 m)(5.1 m)
USDFY, 2014FY, 2015FY, 2016

Cash

8.5 m14.6 m12 m

Inventories

232.6 k497.6 k218.7 k

Current Assets

8.8 m28.1 m25.1 m

Total Assets

8.8 m28.2 m25.2 m

Accounts Payable

341.3 k851.2 k275.4 k

Current Liabilities

1.3 m2.1 m2.3 m

Total Liabilities

3.5 m

Additional Paid-in Capital

1.1 m83.5 m98.9 m

Retained Earnings

(46.5 m)(58.6 m)(77.3 m)

Total Equity

6.3 m24.9 m21.6 m

Financial Leverage

1.4 x1.1 x1.2 x
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

33.6 m30.6 m10.1 m17.6 m14.6 m19.3 m

Current Assets

33.8 m31.2 m23.3 m32.8 m29.1 m31.5 m

Total Assets

33.9 m31.4 m23.4 m32.9 m29.2 m31.5 m

Accounts Payable

629.3 k743.6 k578 k823.3 k733.6 k694.9 k

Current Liabilities

1.4 m1.4 m1.8 m2.4 m2.6 m2.4 m

Additional Paid-in Capital

82.4 m82.9 m84.1 m97.4 m98.3 m110.4 m

Retained Earnings

(50.9 m)(54.2 m)(63.6 m)(67.9 m)(72.6 m)(82.4 m)

Total Equity

31.5 m28.7 m20.5 m29.5 m25.7 m28 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.1 x1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(5.2 m)(12.1 m)(18.7 m)

Depreciation and Amortization

1.1 k18.8 k35.8 k

Inventories

(224.2 k)(265 k)278.9 k

Accounts Payable

(559)509.9 k(575.7 k)

Cash From Operating Activities

5.3 m6.1 m(15.1 m)

Cash From Investing Activities

(14.1 k)(13 m)(225.2 k)

Cash From Financing Activities

10.1 m28.5 m12.7 m

Interest Paid

96.8 k74.3 k78.1 k
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.4 m)(7.7 m)(5 m)(9.3 m)(14 m)(5.1 m)

Depreciation and Amortization

4 k10.6 k8.1 k17.1 k26.5 k9.7 k

Accounts Payable

288.1 k402.3 k(273.1 k)(27.9 k)(117.6 k)419.5 k

Cash From Operating Activities

(3.4 m)(6.3 m)(4.5 m)(7.7 m)(11.2 m)(4.2 m)

Cash From Investing Activities

(31.9 k)(86.1 k)(9.2 k)(2.1 m)(1.5 m)891.5 k

Cash From Financing Activities

28.5 m28.5 m(9.8 k)12.8 m12.7 m10.6 m

Interest Paid

37.7 k55.8 k19.5 k39.1 k58.7 k
Y, 2017

Financial Leverage

1.1 x

Aldeyra Therapeutics Operating Metrics

FY, 2016

Patents (US)

5

Patents Pending

5

Aldeyra Therapeutics Market Value History

Aldeyra Therapeutics Online and Social Media Presence

Aldeyra Therapeutics Company Life and Culture

You may also be interested in